Dyne Therapeutics Inc

DYNNASDAQ · USD
17.16USD0.00 (+0.89%)
115

Dyne Therapeutics Inc (DYN) Covered Calls

Dyne Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 34.52%, average versus the past year. DYN's highest covered call setup is the $27.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 50.08% out of the money with 37 days to expiration, a 50.36% return until expiration, and a 496.81% theoretical annualized return. Across the setups shown, annualized returns run from 196.96% to 496.81% at strikes between $24.00 and $35.00, with 37 to 128 days to expiration, as of Nov 11, 2026.

Read more

Running DYN covered calls helps you generate income from Dyne Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best DYN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If DYN stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling DYN covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given DYN covered call is worth writing.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

2026-12-183727.0050.080.050.30906.0050.36496.81-0.28+0.095590.25
2027-03-1912835.0094.551.303.901831.00101.78290.23-7.23+0.3729,0162.60
2027-01-156527.0050.080.054.90906.0050.36282.80-0.28+0.40254.85
2027-03-1912834.0088.990.154.701616.0089.83256.15-0.83+0.36294.55
2027-03-1912833.0083.440.404.801541.0085.66244.26-2.22+0.38104.40
2027-03-1912832.0077.880.504.401451.0080.66230.00-2.78+0.37673.90
2027-01-156525.0038.970.103.20711.0039.52221.93-0.56+0.353343.10
2027-03-1912831.0072.320.604.901361.0075.65215.73-3.34+0.40394.30
2027-03-1912830.0066.761.004.401301.0072.32206.22-5.56+0.403,5303.40
2027-01-156524.0033.410.304.10631.0035.08196.96-1.67+0.4123.80

As of Nov 11, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank34.52% Moderate
  • Market cap (M$)3,216
  • 52 weeks high-37.14%
  • 52 weeks low22.57%
  • Analyst recommendationStrong Buy
    1.41
  • Target price$34.33
    100.06% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.63
  • EPS growth next 5 years4.57%

As of Nov 13, 2026